# Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

> **NCT00522249** · PHASE1,PHASE2 · TERMINATED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 10 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Pegylated Alfa Interferon
- **DRUG:** sunitinib
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00522249
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-05
- **Final completion:** 2008-07
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** PI decision
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522249, "Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00522249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*